A canine
adenocarcinoma model (CAC-8) of
humoral hypercalcemia of malignancy was evaluated for
transforming growth factors (
TGF)-alpha and -beta, PTH-like activity [
adenylate cyclase-stimulating activity (ACSA)], and in vitro
bone-resorbing activity.
Biological activities present in CAC-8 were separated by reverse phase or
cation exchange HPLC.
TGF alpha in
tumor extract was separated from
TGF beta and ACSA by reverse phase HPLC.
TGF alpha eluted between 26-30%
acetonitrile and was identified by RIA. After the initial reverse phase separation,
TGF beta and ACSA in
tumor extract coeluted between 36-38%
acetonitrile. Sequential
cation exchange followed by reverse phase HPLC separated
TGF beta from ACSA. Evaluation of fractions containing ACSA using an in vitro bone-resorbing assay demonstrated copurification of ACSA and
bone-resorbing activity. The PTH receptor antagonist [Nle8,18,Tyr34]bovine PTH-(3-34)-amide, but not [Nle8,18,Tyr34]bovine PTH-(7-34)-amide, completely inhibited ACSA in column eluates. Conditioned cell culture medium from CAC-8 primary cultures contained predominantly latent
TGF beta that could be activated by acidification. These findings indicate that the CAC-8 model of
cancer-associated
hypercalcemia produces a PTH-like factor,
TGF alpha, and
TGF beta that were separable by reverse phase or
cation exchange HPLC. This feature should be useful to investigate the role of TGFs and PTH-like
proteins in the pathogenesis of
humoral hypercalcemia of malignancy.